Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Joslin Scientists Find That Salsalate… >

Joslin Scientists Find That Salsalate Lowers Blood Glucose in Type 2 Diabetes

Published: July 2, 2013.
Released by Joslin Diabetes Center  

BOSTON – July 1, 2013 -- Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

The scientists became interested in studying salsalate, an anti-inflammatory drug, after research conducted by Steven Shoelson, M.D., Ph.D., Head of the Section on Pathophysiology and Molecular Pharmacology and Professor of Medicine at Harvard Medical School, identified inflammation as a factor in the development of type 2 diabetes.

Stage 1 of TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) evaluated varying doses of salsalate in 108 participants with type 2 diabetes for 14 weeks. This study was reported in the Annals of Internal Medicine in 2010. The current findings are based on Stage 2 of TINSAL-T2D, which evaluated 286 participants with type 2 diabetes for 48 weeks. The subjects' blood glucose was inadequately controlled on current diabetes medications. Participants were randomized into salsalate and placebo groups.

After 48 weeks of treatment, the mean hemoglobin A1c level (a measurement of average blood glucose control over the past six to twelve weeks) was 37 percent lower in the salsalate group compared to the placebo group. The decrease in fasting glucose concentration was 15 mg/dl greater in the salsalate group than the placebo group. Patients in the salsalate group required fewer additional diabetes medications to control their blood sugar than patients in the placebo group.

"It's exciting that salsalate is effective in lowering blood sugar," says Allison Goldfine, M.D., lead author and Head of the Section of Clinical, Behavioral and Outcomes Research, and an Associate Professor of Medicine at Harvard Medical School. "Salsalate may have an important role in diabetes treatment and may also help us learn more about how inflammation contributes to the development of type 2 diabetes."

The salsalate group also showed improvements in markers associated with coronary risk: a 9 percent reduction in triglycerides and a 27 percent increase in adiponectin, a potentially cardioprotective protein from adipocytes. Uric acid, which is associated with cardiometabolic conditions and progression of renal disease, decreased 18 percent in the salsalate group. "The reductions in these cardiovascular risk factors paralleled improved glycemia," says Dr. Goldfine. However, the salsalate group also exhibited modest increases in LDL cholesterol and urine albumin, and had a slight increase in weight, which can indicate negative effects on heart or kidney function.

Salsalate's anti-inflammatory effects were evidenced by reductions in circulating white blood cells, neutrophils and lymphocytes, which are elevated in obesity and metabolic syndrome, but all remained within normal range.

The next step in determining whether salsalate is a safe drug for use as a diabetes medication and can receive FDA approval is to assess its effects on the progression of heart disease. Dr. Goldfine is currently leading a study, TINSAL-CVD, which is evaluating how salsalate affects coronary artery plaque volume in participants with established coronary artery disease. The results should be available in two years. "The study will help us better understand the risk/benefit ratio of using salsalate to treat diabetes," says Dr. Goldfine.




The above story is based on materials provided by Joslin Diabetes Center.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Graft 
7/23/13 
BMC Surgeon Recommends Off-pump Coronary Artery Bypass Grafting Be Abandoned
(Boston) - In a Special Report in the current issue of Circulation, Boston Medical Center cardiothoracic surgeon Harold Lazar, …
Percent 
11/5/12 
Bypass Surgery Improves Survival for Patients with Diabetes And Multi-vessel Coronary Artery Disease
(Toronto – Nov. 4, 2012) – An international, clinical research trial has shown that patients with diabetes whose multi-vessel …
Surgery 
9/13/13 

Study Finds 30% Lower Risk of Dying for Diabetics with Bypass Surgery Vs. Stent
Alzheimer 
10/30/13 
Persons with Alzheimer's Are More Likely to Suffer from Heart Disease - Yet Offered Less Treatment Options Than Others
Persons with Alzheimer's disease suffer from ischaemic heart diseases more frequently than others, yet they undergo related procedures and …
Vessels 
9/30/11 
'Back-up System' Reduces Heart Disease Deaths
Small bypass vessels which act as a 'back-up system' for the heart's main arteries play a significant role in …
Patients 
3/14/12 
Beating Heart Surgery May Increase Risk to Patients
Coronary artery bypass surgery performed whilst the heart is still beating may carry an increased likelihood of death, according …
Mitral 
2/29/12 
Mitral Valve Repair with Bypass Surgery May Improve Heart Function
Patients who had leaky mitral heart valves repaired along with bypass surgery had with healthier hearts than those who …
Disease 
4/3/13 
Baldness Linked to Increased Risk of Coronary Heart Disease
Male pattern baldness is linked to an increased risk of coronary heart disease, but only if it's on the …
More » 
 
© Newsline Foundation  |  About  |  Privacy Policy  |  Feedback  |  Mobile